Gemina Laboratories Ltd.
GLAB
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.22% | 10.02% | 10.70% | 23.90% | 47.25% |
| Total Depreciation and Amortization | -43.25% | -17.40% | 10.51% | 18.79% | 34.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.37% | -9.00% | 16.65% | 4.83% | -78.07% |
| Change in Net Operating Assets | 31.09% | 47.68% | 56.48% | 52.18% | 0.93% |
| Cash from Operations | 100.03% | 84.57% | 76.94% | 60.29% | 65.22% |
| Capital Expenditure | -- | -- | -- | -- | 119.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 8.33% | 319.35% | 336.36% | 142.35% | 103.16% |
| Total Debt Issued | -100.00% | -95.28% | -95.28% | 355.00% | 355.00% |
| Total Debt Repaid | 31.71% | 32.38% | 1.18% | -29.87% | -39.36% |
| Issuance of Common Stock | -98.14% | -98.14% | -- | -83.82% | -85.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 118.32% | 46.69% | 46.69% | 75.58% | 70.35% |
| Cash from Financing | -104.62% | -101.93% | -50.84% | -60.13% | -63.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -208.24% | -343.14% | 101.26% | 100.70% | 106.31% |